ARAV(Delisted)
Aravive·NASDAQ
--
--(--)
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ARAV
Aravive, Inc.
A late clinical-stage oncology company that develops targeted therapeutics to treat metastatic disease
River Oaks Tower, 3730 Kirby Drive, Suite 1200, Houston, Texas 77098
--
Aravive, Inc. (Nasdaq: ARAV effective October 16, 2018) is a clinical-stage biotechnology company focused on the development of innovative therapies for cancer survival pathways. Aravive's main candidate, AVB-S6-500, is a novel high-affinity soluble Fc fusion protein designed to block the activation of the GAS 6-AXL signaling pathway by intercepting the binding of GAS 6 to its receptor AXL. AXL receptor signaling plays an important role in treatment resistance and immunosuppression in many types of malignancies by hindering cancer cell survival. Aravive expects to initiate the Phase 1b portion of the Phase 1b/2 clinical trial of AVB-S6-500 in combination with standard treatment for platinum-resistant ovarian cancer patients by the end of 2018, and intends to develop it into a new anti-tumor business.
Company Financials
EPS
ARAV has released its 2023 Q2 earnings. EPS was reported at -0.12, versus the expected -0.29, beating expectations. The chart below visualizes how ARAV has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ARAV has released its 2023 Q3 earnings report, with revenue of 2.76M, reflecting a YoY change of -44.39%, and net profit of 21.23M, showing a YoY change of 235.52%. The Sankey diagram below clearly presents ARAV's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
